Body composition changes in diabetes and aging

被引：104
作者：
Al-Sofiani, Mohammed E. [1 ,2 ]
Ganji, Suneeta S. [1 ]
Kalyani, Rita R. [1 ]
机构：
[1] Johns Hopkins Univ, Div Endocrinol Diabet & Metab, Baltimore, MD USA
[2] King Saud Univ, Coll Med, Div Endocrinol, Riyadh, Saudi Arabia
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2019年 / 33卷 / 06期
基金：
美国国家卫生研究院;
关键词：
Diabetes; Body composition; Lean mass; Fat mass; Aging; Muscle mass; ADIPOSE-TISSUE DISTRIBUTION; LIVER FAT-CONTENT; MUSCLE STRENGTH; GLYCEMIC CONTROL; OLDER-ADULTS; RESISTANCE EXERCISE; INSULIN SENSITIVITY; VISCERAL ADIPOSITY; ENERGY-EXPENDITURE; GLUCOSE-TOLERANCE;
D O I：
10.1016/j.jdiacomp.2019.03.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aging is associated with changes in body composition, including both fat gain and muscle loss beginning in middle age, and is associated with increased risk of type 2 diabetes. Moreover, changes in fat distribution take place in adults as they age and may contribute to the increased risk of type 2 diabetes. Recent literature has shown differences in the age-related changes in body composition by diabetes status suggesting that some of these changes might not only be a risk factor of the development of diabetes but could also be a consequence of the disease. In this article, we review the current evidence on body composition changes that take place in adults after the diagnosis of type 2 diabetes and compare them to those observed in adults without diabetes as they age. We also review the effect of various lifestyle, pharmacological, and surgical treatments that lower blood glucose on body composition in adults with type 2 diabetes. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码：451 / 459
页数：9
相关论文
共 80 条
  • [21] Changes in Adipose Tissue Depots and Metabolic Markers Following a 1-Year Diet and Exercise Intervention in Overweight and Obese Patients With Type 2 Diabetes
    Gallagher, Dympna
    Heshka, Stanley
    Kelley, David E.
    Thornton, John
    Boxt, Lawrence
    Pi-Sunyer, F. Xavier
    Patricio, Jennifer
    Mancino, Juliet
    Clark, Jeanne M.
    [J]. DIABETES CARE, 2014, 37 (12) : 3325 - 3332
  • [22] Metformin and body weight
    Golay, A.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 (01) : 61 - 72
  • [23] Goodpaster BH, 2000, AM J CLIN NUTR, V71, P885
  • [24] Laparoscopic gastric banding and body composition in morbid obesity
    Guida, B
    Belfiore, A
    Angrisani, L
    Micanti, F
    Mauriello, C
    Trio, R
    Pecoraro, P
    Falconi, C
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2005, 15 (03) : 198 - 203
  • [25] The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
    Harder, H
    Nielsen, L
    Thi, TDT
    Astrup, A
    [J]. DIABETES CARE, 2004, 27 (08) : 1915 - 1921
  • [26] Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes
    Hartemann-Heurtier, Agnes
    Halbron, Marine
    Golmard, Jean-Louis
    Jacqueminet, Sophie
    Bastard, Jean-Philippe
    Rouault, Christine
    Ayed, Amine
    Pieroni, Laurence
    Clement, Karine
    Grimaldi, Andre
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 86 (01) : 37 - 43
  • [27] Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgery
    Heath, Madeleine L.
    Kow, Lilian
    Slavotinek, John P.
    Valentine, Robin
    Toouli, Jim
    Thompson, Campbell H.
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (06): : 753 - 758
  • [28] Longitudinal changes in body composition in older men and women: role of body weight change and physical activity
    Hughes, VA
    Frontera, WR
    Roubenoff, R
    Evans, WJ
    Singh, MAF
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 76 (02) : 473 - 481
  • [29] Inoue H, 2018, J DIABETES INVEST, DOI [10.1111/jcli.12985, DOI 10.1111/JCLI.12985]
  • [30] Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
    Jendle, J.
    Nauck, M. A.
    Matthews, D. R.
    Frid, A.
    Hermansen, K.
    During, M.
    Zdravkovic, M.
    Strauss, B. J.
    Garber, A. J.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (12) : 1163 - 1172
12345678